Seres Therapeutics(MCRB)
Focus: Seres Therapeutics is a public biotech company focused on developing microbial therapeutics to counteract antibiotic side effects, primarily in infectious diseases. The company operates as a mid-cap biotech with a clinical-stage pipeline and is publicly traded on NASDAQ under ticker MCRB.
Profile data last refreshed 16h ago · AI intelligence enriched 3w ago
Funding Stage
PUBLIC
Open Jobs
4-1 this month
Stable — net -1 jobs in 30d
0 added, 1 removed. Backfill posture.
Should You Work at Seres Therapeutics?
AI assessmentSeres offers early-stage career exposure to an innovative therapeutic area, but severe cash depletion and minimal hiring present substantial stability risk for risk-averse candidates.
Why Work Here
- Pioneering microbiome therapeutics in a novel, undercrowded space with only 8 active clinical trials across multiple indications (C. difficile, ulcerative colitis, HSCT)
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
2 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Revenue
$0K
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT02437500Expanded Access Program of SER-109 in the Treatment of Adults With Recurrent Clostridioides Difficile Infection (RCDI)
N/AHelp build intelligence for Seres Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.